跳至主要内容
临床试验/NCT02043171
NCT02043171已完成1 期

Year-long Double Blind Study on the Efficacy of a Combination of Beta-hydroxy-beta-methylbutyrate and Vitamin D With and Without Exercise on Muscular Strength and Functionality in Older Adults.

Metabolic Technologies Inc.1 个研究点 分布在 1 个国家目标入组 238 人开始时间: 2014年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
238
试验地点
1
主要终点
Muscular strength

研究概览

简要总结

Men and women lose muscle mass and strength with age. Loss of muscle mass and strength is accompanied by a loss of muscle function which can lead to diminished quality of life and more importantly can lead to serious fall requiring medical treatment. The investigators hypothesize that the combined supplements of Calcium-HMB and Vitamin D will lead to decreased falls and to improved quality of life (QOL) for older adults. The investigators further hypothesize that the addition of a modest exercise regimen to these supplements will enhance the synergistic effects of both Calcium-HMB and Vitamin D.

Subjects will consume the dietary supplement 2 times per day for 12 months. Tests will consist of the following: a) strength of subjects' legs and elbow by Isokinetic Dynamometer; b) body composition; c) hand-grip strength by hand-grip dynamometer; d) functional mobility, balance and agility (Get-Up and Get-Up-and-Go tests); e) filling out questionnaires; and g) having blood drawn for biochemical measurements. Testing will be performed at the baseline (0 months) and at 3, 6, 9, and 12 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subjects will be enrolled into the study.
  • Age > 60 years.
  • Free of liver and kidney diseases, and with no evidence of uncontrolled hypertension.
  • Does not have a chronic disease that affects calcium or bone metabolism (i.e., asthma with chronic use of high dose steroids, inflammatory bowel disease, Crohn's disease, primary hyperparathyroidism, seizure disorder with use of phenobarbital, etc.).
  • Not classified as morbidly obese (body mass index (BMI) >40 kg/m2).
  • Six weeks since major surgery (three weeks since minor surgery).
  • Willing to consume one of the nutritional supplements for the study period.
  • Individuals diagnosed with osteoporosis, or bone density > 2.0 standard deviations below the mean, will not be enrolled in the study.
  • No other serious medical illness.
  • Serum 25OH-vitD3 >15 ng/ml.
  • Willing to participate in 3-day-a-week monitored strength-training program.
  • Physician has placed no restriction on physical exercise.

排除标准

  • Age < 60 years.
  • Evidence of liver and kidney diseases, uncontrolled hypertension, or Type I diabetes mellitus requiring insulin for glucose control.
  • Presence of a chronic disease that affects calcium or bone metabolism (i.e., asthma with chronic use of high dose steroids, inflammatory bowel disease, Crohn's disease, primary hyperparathyroidism, seizure disorder with use of phenobarbital, etc.).
  • Classified as morbidly obese (body mass index (BMI) >40 kg/m2).
  • Less than six weeks since major surgery or three weeks since minor surgery.
  • Not willing to consume one of the nutritional supplements for the study period.
  • Individuals diagnosed with osteoporosis, or a bone density > 2.0 standard deviations below the mean, will not be enrolled in the study.
  • Other serious medical illness, which the subject's doctor or medical review team has decided affects the subject's ability to participate in the study.
  • History of blood clots and/or the use of blood thinning medications
  • Subjects on high dose vitamin D therapies (i.e. 50,000 IU vitamin D).
  • Subjects with serum 25OH-vitD3 <10 ng/ml will be considered deficient and will be referred to their physician for treatment.
  • Subjects with serum 25OH-vitD3 >30 ng/ml may not respond to the intervention as expected and will also be excluded from the study.
  • Not able or willing to participate in 3-day-a-week monitored strength-training program.
  • Physician has placed a restriction on physical exercise.

研究组 & 干预措施

Placebo Exercise

Placebo Comparator

Placebo supplementation group with 3 days per week of exercise

干预措施: Placebo (Dietary Supplement)

Placebo Exercise

Placebo Comparator

Placebo supplementation group with 3 days per week of exercise

干预措施: Exercise (Behavioral)

Placebo Non-exercise

Placebo Comparator

Placebo supplementation group without exercise

干预措施: Placebo (Dietary Supplement)

Placebo Non-exercise

Placebo Comparator

Placebo supplementation group without exercise

干预措施: Non-Exercise (Behavioral)

HMB plus Vitamin D Exercise

Active Comparator

HMB plus Vitamin D supplementation group with 3 days per week of exercise

干预措施: HMB plus Vitamin D (Drug)

HMB plus Vitamin D Exercise

Active Comparator

HMB plus Vitamin D supplementation group with 3 days per week of exercise

干预措施: Exercise (Behavioral)

HMB plus Vitamin D Non-exercise

Active Comparator

HMB plus Vitamin D supplementation group without exercise

干预措施: HMB plus Vitamin D (Drug)

HMB plus Vitamin D Non-exercise

Active Comparator

HMB plus Vitamin D supplementation group without exercise

干预措施: Non-Exercise (Behavioral)

结局指标

主要结局

Muscular strength

时间窗: 12 Months

Leg and elbow strength will be tested by Isokinetic dynamometer and Handgrip strength will be tested using a hand-grip dynamometer.

次要结局

  • Functionality(12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验